Rubicon Research

** Drug formulations firm Rubicon Research's RUBI.NS shares rise 12.2% to 1,128 rupees, touching an all-time high

** Q4 profit jumps 111.8%; revenue from operations up 43.5%

** Recommends dividend of 1.5 rupees/shr

** Says revenue traction is likely to continue to be stronger than anticipated

** Adds, strong revenue traction coupled with own manufacturing capacity constraint had led to a larger reliance on outsourced manufacturing since the last quarter

** Says larger than anticipated reliance on outsourced manufacturing could further contract gross margin % in the near term

** 24 products were under review by U.S. FDA as of 31 March, RUBI.NS says

** YTD, stock up 66% vs 1% decline in Nifty Smallcap 500 Index .NIFTYSMALLCAP500

(Reporting by Abhinav Parmar in Bengaluru)

(([email protected];))

April 22 (Reuters) - Rubicon Research Ltd RUBI.NS:

• RUBICON RESEARCH LTD - TOTAL DEMAND RAISED AMOUNTS TO 172.5 MILLION RUPEES

• RUBICON RESEARCH LTD - RECEIVES ORDER FROM INCOME TAX AUTHORITY

Source text: ID:nBSE5MWsZ

Further company coverage: RUBI.NS

(([email protected];))

April 15 (Reuters) - Rubicon Research Ltd RUBI.NS:

• TO BUY 85% STAKE IN ARINNA LIFESCIENCES

• DEAL VALUED AT 1.76 BILLION RUPEES

• DEAL FOR PRICE OF ABOUT 158.53 RUPEES PER SHARE

Source text: ID:nBSE387jMF

Further company coverage: RUBI.NS

(([email protected];;))

** Shares of Rubicon Research RUBI.NS jump as much as 13% to a record high of 789 rupees, last up 4%

** Stock up for a third straight session

** Pharmaceutical formulations co's Q3 consol net profit nearly doubles to 728 mln rupees ($8.04 mln); rev from ops rises 51.7% y/y

** Stock up about ~21 from market debut in October 16, 2025

($1 = 90.5200 Indian rupees)

(Reporting by Brijesh Patel in Bengaluru)

(([email protected]; Ph no. +91 9590227221;))

Feb 3 (Reuters) - Rubicon Research Ltd RUBI.NS:

• DEC-QUARTER CONSOL NET PROFIT 728 MILLION RUPEES

• DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 4.76 BILLION RUPEES

Source text: ID:nBSE4GS3ZJ

Further company coverage: RUBI.NS

(([email protected];))

Jan 30 (Reuters) - Rubicon Research Ltd RUBI.NS:

• TAX AUTHORITIES COMMENCE INSPECTION AT COMPANY OFFICES

• COMPANY FULLY COOPERATING WITH OFFICIALS

• BUSINESS OPERATIONS CONTINUE UNIMPACTED BY INSPECTION

Source text: ID:nNSE3Fv1J4

Further company coverage: RUBI.NS

(([email protected];))

Jan 6 (Reuters) - Rubicon Research Ltd RUBI.NS:

• RUBICON RESEARCH LTD - UNIT GETS TAX DEMAND OF 41.9 MILLION RUPEES

Source text: ID:nNSE2lyKrH

Further company coverage: RUBI.NS

(([email protected];))

Nov 13 (Reuters) - Rubicon Research Ltd RUBI.NS:

• RUBICON RESEARCH SEPT-QUARTER CONSOL NET PROFIT 538.5 MILLION RUPEES

• RUBICON RESEARCH SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 4.12 BILLION RUPEES

Source text: [ID:]

Further company coverage: RUBI.NS

(([email protected];))

** Shares of pharmaceutical formulations co Rubicon Research RUBI.NS rise 2.3% to 623 rupees

** Motilal Oswal initiates coverage with "buy" rating, PT of 740 rupees; first brokerage to cover stock - per data compiled by LSEG

** Brokerage estimates annualised growth of 29%, 32%, and 43% in rev, EBITDA, and PAT, respectively
** Says growth driven by new generic launches, stronger focus on prescription-led business in CNS therapy, stable

R&D productivity, tighter supply chain management

** Adds, Rubicon's consistent compliance track record provides a strong backbone for growth in earnings and

return ratios

** Since its listing earlier this month, RUBI down nearly 3%

(Reporting by Yagnoseni Das in Bengaluru)

(([email protected];))